2021
DOI: 10.1101/2021.12.08.21267417
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Abstract: The emergence of the Omicron variant (1) of SARS-CoV-2 in November 2021 in South Africa has raised concerns that, based on the large number of mutations in the spike protein and elsewhere on the virus (https://covdb.stanford.edu/page/mutation-viewer/#sec_b-1-351), this variant will have considerable escape from vaccine elicited immunity. Furthermore, several mutations in the receptor binding domain and S2 are predicted to impact transmissibility and affinity for ACE-2. Here we investigated whether Omicron esc… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

17
295
3
1

Year Published

2021
2021
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 351 publications
(326 citation statements)
references
References 25 publications
17
295
3
1
Order By: Relevance
“…In contrast, a significant number of patients with hematological malignancies still had undetectable neutralizing responses following a third vaccine dose, especially against VOCs, and remain at risk of breakthrough infection. These findings are particularly pertinent given reports of reduced vaccine efficacy and NAb activity against the emerging Omicron VOC compared to Delta ( Cele et al., 2021 ).…”
mentioning
confidence: 88%
“…In contrast, a significant number of patients with hematological malignancies still had undetectable neutralizing responses following a third vaccine dose, especially against VOCs, and remain at risk of breakthrough infection. These findings are particularly pertinent given reports of reduced vaccine efficacy and NAb activity against the emerging Omicron VOC compared to Delta ( Cele et al., 2021 ).…”
mentioning
confidence: 88%
“…40 Meanwhile, the sera from vaccinated individuals also had about 40 lower neutralizing ability against the Omicron variant compared to the wild-type SARS-CoV-2. 41 These results suggested that the present COVID-19 vaccines might not be effective against the Omicron variant as other SARS-CoV-2 variants. More data about the effectiveness of current COVID-19 vaccines need to be further investigated in the future.…”
Section: Developing Variant-specific Vaccinesmentioning
confidence: 82%
“…These data, although derived from a relatively small sample size, are consistent with published data from datasets of similar size. 4 , 5 , 6 Together, the findings suggest that omicron is more antigenically distant from the original SARS-CoV-2 vaccine strain than the previously most distant strains, beta and delta. Preliminary data from the UK Health Security Agency 7 have shown reduced effectiveness against symptomatic infection after two doses of ChAd or BNT, suggesting a result of increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection.…”
mentioning
confidence: 82%
“…The data underpinning the victoria, beta, and delta neutralisation have been previously reported. 4 The horizontal dotted line indicates half the value of the lower limit of detection. The red horizontal lines in (A) and (B) represent the assay limit of detection and the red numbers represent the median values of the FRNT 50 .…”
mentioning
confidence: 99%